Find Paid Research Studies in Bend, Oregon

Browse Locations ... United States» ... Oregon» ... Bend

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013
Video Impact on Neulasta Education

Condition: Breast Cancer
Interventions: Other: Educational DVD 1; Other: Educational DVD 2
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
NOLAN: Naproxen or Loratadine and Neulasta

Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen; Drug: Loratadine
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013
A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: OMP-59R5; Drug: Gemcitabine; Drug: Placebo; Drug: Nab-Paclitaxel
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.
Recruiting - verified March 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified April 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Condition: Neoplasms, Breast
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Condition of Approval Study

Condition: Lumbar Spinal Stenosis
Intervention: Device: X-STOP PEEK
Sponsors: Medtronic Spine LLC; Medtronic Spine LLC
Recruiting - verified April 2013
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013

Find Paid Research Studies in Bend, Oregon

Welcome to Paid Research Studies.